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Key Clinical Message
GHB intoxication must be considered in children with coma and a suspicion of
drug intoxication. Furthermore, mixed intoxication with several substances and
the possibility of unpredictable symptom profiles should be anticipated to
ensure optimal symptomatic treatment of patients.
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Introduction
Gamma-Hydroxybutyrate (GHB) is an endogenic gamma-
aminobutyric acid analog originally used in the 1960s as
an anesthetic drug. It was revoked due to side effects but
later reintroduced as a drug for treatment of narcolepsy.
In the 1980s GHB was promoted as a bodybuilding and
weight loss aid due to its purported growth hormone
stimulatory effects [1, 2]. After it was banned in the US
in 1990, its use in body building [3] and as a recreational
drug [4] expanded. GHB reached the UK in the mid
1990s [5] and shortly thereafter Denmark as a substance
of abuse [6]. The prevalence of GHB use in Scandinavia
is considered to be low, but the proportion of intoxica-
tions with GHB relative to other drugs-of-abuse is high
and numerous fatalities have been described [7].
Gamma-butyrolactone (GBL) and 1,4-butanediol (BD)
are prodrugs of GHB. Both substances are accessible as
pure industrial solvents (>98%) and purchasing opportu-
nities as well as recipes for converting these prodrugs into
GHB are easily available [8]. The legal status of GBL and
BD vary and only a few countries have classified the com-
pounds as controlled substances.
GHB, GBL, and BD intoxication in children has been
described. Accidental ingestion of GBL solvents [9–11],
ingestion of BD coated toy beads [12–15], and cases of
children and adolescents unintentionally drinking GHB
laced soft drinks have been reported [16, 17]. We report
a case of a 3-year-old boy ingesting GHB from a fluid
container found in a fitness center. To our knowledge,
GHB intoxication in children as a result of the substance’s
supposed growth hormone stimulatory effects and misuse
among bodybuilders has not been reported before.
Case
A 3-year-old Danish boy was admitted to hospital with
sudden onset lethargy, vomiting, and unconsciousness.
The child was with his father in a fitness center, where he
was left unsupervised in a children’s play area. Shortly
after, the child came up to his father and said that he had
drunk something from a fluid container left on a nearby
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table. Approximately 40 min later, when the family was
eating at a nearby restaurant, the child suddenly became
lethargic and distant and was rushed to hospital.
Upon arrival the patient was cyanotic and unconscious
with a Glasgow Coma Score (GCS) of 8 and a saturation
of 84%. All other vital parameters were normal. Initial
blood sugar was 5.2 mmol/L. The patient exhibited
equally dilated pupils that had slow response to light
bilaterally. The patient woke up after 10 min and after
another 15 min was fully awake with a GCS of 15. Active
charcoal was given. Initial blood tests including hemoglo-
bin, capillary blood gas, kidney, electrolyte, liver enzyme,
and infection parameters were normal. Plasma ethanol
was below 3.0 mmol/L. Since the hospital did not have a
pediatric department, the patient was transferred to an
appropriate hospital for observation.
Approximately 90 min after time of ingestion, the
patient again suddenly became bradycardic and desatu-
rated to 60%. The patient exhibited dilated pupils and
increased tonus in his hands and arms, but showed other-
wise no signs of cramping. The patient improved sponta-
neously within 3 min with normal pulse and saturation
but fell into deep sleep. Cerebral CT was normal. Contin-
uous ECG monitoring showed sinus rhythm. A urine
sample was acquired by bladder puncture. A urine toxi-
cology screening (immunoassay panel test) was negative
for amphetamines, benzodiazepines, cocaine metabolites,
cannabis, cannabis metabolites, methadone, and opiates.
A urine sample was saved for further testing. The patient
was stabilized without ABC problems, but with continued
lowered GCS. He was transferred to the intensive care
unit where repeated blood tests were normal. Approxi-
mately 6 h after ingestion, the patient woke up and pre-
sented no further symptoms.
The patient’s father was aware of GHB use in the fit-
ness center. On the basis of the symptoms as well as the
history, we suspected GHB intoxication. Isocratic high-
performance liquid chromatography with tandem mass
spectrometry (LC-MS/MS) was used to determine GHB
and prodrugs with a method adopted from Wood et al.
[18] using a Symmetry C18 column, 2 9 100 mm
(3.5 lm) from Waters. The GHB concentration in the
patient’s urine sample retrieved 1.5–2 h after ingestion
was 186 lg/mL. GBL was 15 lg/mL and BD was not
detected. The urinal cut-off concentration used to distin-
guish exogenous GHB ingestion from endogenous levels
is 10 lg/mL.
Discussion
The urine GHB concentration found in this case report
(186 lg/mL) was 18 times higher than the maximum
endogenous level. In comparison, a study of 8 healthy
adult volunteers who were administered a single 25 mg/
kg dose of GHB showed peak urine concentrations of
230  86.3 lg/mL 60 min after ingestion [19]. Another
study of 12 adult volunteers ingesting the same dose of
GHB reported peak concentrations in the range 32.6–
161.3 lg/mL (average 67.6 lg/mL) [20]. In a study of 16
adult volunteers, doses of 50 mg/kg resulted in peak urine
concentrations averaging 150–200 lg/mL in samples
collected 0–3 h after drug administration [21]. Due to
insufficient urine sample volume, it was not possible to
determine the creatinine level of our patient’s urine sam-
ple. We are, therefore, unable to comment on the degree
of urinal dilution. We can, however, conclude that the
urine GHB concentration in this case report corresponds
to levels found in adults who are administered GHB doses
of 25–50 mg/kg.
Our case demonstrates previously described symptoms
of GHB toxicity. These are vomiting, lethargy, somno-
lence, respiratory distress, bradycardia, and CNS depres-
sion. The patient showed sudden onset of symptoms and
spontaneous remission – two very characteristic traits of
GHB intoxication [22]. One symptom that did not fit the
profile of GHB intoxication, however, was the dilation of
the patient’s pupils.
The patient’s symptom pattern exhibited a biphasic
profile. Sedative symptoms with affected GCS appeared
twice, initially 40 min after ingestion and then again 1.5–
2 h after ingestion. GHB is known to show a mixed stim-
ulant-sedative pattern where psychostimulant effects
appear first and sedative effects appear later [23]. A dou-
ble-peaked sedative effect, however, has not been
described previously. It is known that elimination of
GHB from the body is biphasic. The first phase follows
linear, zero-order kinetics where the rate of elimination is
independent of the drug concentration. Remaining elimi-
nation follows a inversely proportional, concentration-
dependent first-order kinetic rate of elimination [19, 24,
25]. A biphasic symptom profile should, therefore, not be
possible.
The biphasic clinical presentation of symptoms raises
the suspicion of the possible involvement of other toxic
agents. The observed dilated pupils support this suspicion
but at the same time could have been the result of
parasympathetic effects caused by vomiting and a fall in
blood pressure, pulse, and respiration frequency. Subse-
quent comprehensive urine drug screening was, therefore,
carried out to determine the possible presence of other
drugs not detected in the immunoassay panel test. A low
concentration of benzoylecgonine – a metabolite of
cocaine – estimated to 20 ng/mL was found by LC-MS/
MS. The combination of GHB and cocaine is well-known
in the world of fitness and bodybuilding, where the
stimulatory effects of cocaine are used to counteract the
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sedative effects of GHB. The presence of cocaine in con-
junction with GHB in our patient was, therefore, not
surprising.
Initial urine analysis by immunoassay was false negative
for cocaine. Screening tests for benzoylecgonine have cut-
off concentrations between 150 and 300 ng/mL and
concentrations less than this remain undetectable. Since
the amount of cocaine in the urine sample was below the
limit of quantification and because the patient received
active charcoal within the appropriate time interval, we
believe that this treatment may have terminated further
absorption of cocaine.
Another factor that needs to be considered is the effect
of food on the symptom profile of GHB and cocaine. The
patient had eaten a meal shortly after ingesting the
unknown fluid. Food could have played a role in the
absorption rate of both GHB and cocaine and may have
contributed to the biphasic symptom profile seen.
Another plausible cause of the biphasic profile seen in
our patient may be ingestion of a mixture of GHB, GBL
and/or BD. It is known that both prodrugs of GHB have
the same toxic effects as GHB but GBL has more rapid
absorption, greater lipid solubility, higher serum concen-
tration, and more prolonged hypnotic effects than GHB
[26–28]. The concentration of GBL and GHB in urine is,
however, inconclusive with regard to GBL ingestion due
to the dynamic equilibrium that exists between GHB and
GBL in vitro [29].
Hence, it remains speculative whether a mixture of
GBH, GBL and/or BD could produce the symptom profile
observed in our patient or if it may have been caused by
food ingestion or by the presence of other drugs that
were not detected. On the basis of our patient’s clinical
presentation and resolution of symptoms and a confirma-
tory high urine level of GHB, we conclude that GHB was
the most likely cause of our patient’s symptoms.
Conclusion
GHB intoxication must be considered in children with
coma and a suspicion of drug intoxication. Furthermore,
mixed intoxication with several substances and the possi-
bility of unpredictable symptom profiles should be antici-
pated to ensure optimal symptomatic treatment of
patients. The use of GHB and cocaine in the world of
bodybuilding and our account of a new child victim
demonstrates a new area of concern.
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